Entera Bio (NASDAQ:ENTX) Shares Gap Down – What’s Next?

Entera Bio Ltd. (NASDAQ:ENTX) gapped down before the market opened on Tuesday. The stock had previously closed at $2.94, but opened at $2.79. Entera Bio shares last traded at $3.1070, with a volume of 38,567 shares.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on ENTX shares. Cantor Fitzgerald started coverage on Entera Bio in a report on Tuesday, September 22nd. They set an “overweight” rating for the company. Wall Street Zen upgraded shares of Entera Bio to a “sell” rating in a report on Saturday, August 8th. HC Wainwright reiterated a “buy” rating on shares of Entera Bio in a report on Wednesday, June 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Entera Bio in a research report on Thursday. Finally, UBS Group set a $9.00 target price on shares of Entera Bio in a research note on Friday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Entera Bio currently has an average rating of “Moderate Buy” and a consensus target price of $9.60.

Entera Bio Stock Up 7.3%

The company has a market cap of $548.72 million, a P/E ratio of -9.01 and a beta of 1.40. The stock has a 50 day moving average price of $2.88 and a two-hundred day moving average price of $2.04.

Entera Bio (NASDAQ:ENTX) last released its quarterly earnings results on Friday, August 7th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.06). Equities analysts anticipate that Entera Bio Ltd. will post -0.40 EPS for the current year.

Institutional Investors Weigh In On Entera Bio

An institutional investor recently raised its stake in Entera Bio stock. Renaissance Technologies LLC lifted its holdings in Entera Bio Ltd. (NASDAQ:ENTX) by 338.4% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 473,442 shares of the company’s stock after acquiring an additional 365,441 shares during the period. Renaissance Technologies LLC owned approximately 0.96% of Entera Bio worth $526,000 as of its most recent filing with the SEC. 14.11% of the stock is currently owned by hedge funds and other institutional investors.

Entera Bio Company Profile

Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing orally delivered biologic medicines. The company’s proprietary platform is designed to enable the oral administration of large-molecule therapies, including peptides and proteins that are traditionally delivered by injection.

Entera Bio’s pipeline has included EB613, an oral formulation of parathyroid hormone fragment (teriparatide) being developed for the treatment of osteoporosis, and EB612, an oral parathyroid hormone product intended for hypoparathyroidism.